The Efficacy Of Ranibizumab In The Treatment Of Macular Edema Second
Versandkostenfrei!
Versandfertig in 6-10 Tagen
33,99 €
inkl. MwSt.
PAYBACK Punkte
17 °P sammeln!
Retinal vein occlusion ( RVO ) causes significant visual loss in patients with medical diseases especially systemic hypertension . Centrally involving macular edema is the main cause of loss of vision in such patients . previous treatment strategies for macular edema involve argon laser retinal photocoagulation , Radial optic neurotomy, intravitreal injections of steroids but recently the introduction of anti-vascular endothelial growth factor medications represents a breakthrough and has revolutionized the treatment of retinal vein occlusion associated macular edema in addition to the benefic...
Retinal vein occlusion ( RVO ) causes significant visual loss in patients with medical diseases especially systemic hypertension . Centrally involving macular edema is the main cause of loss of vision in such patients . previous treatment strategies for macular edema involve argon laser retinal photocoagulation , Radial optic neurotomy, intravitreal injections of steroids but recently the introduction of anti-vascular endothelial growth factor medications represents a breakthrough and has revolutionized the treatment of retinal vein occlusion associated macular edema in addition to the beneficial effect of suppressing the risky retinal neovascularization . Ranibizumab ( Lucentis ) is one of the most commonly used Anti-VEGF drugs in treatment of macular edema associated with retinal vein occlusion RVO whether the central type ( CRVO ) or the branch type ( BRVO ) .
Andere Kunden interessierten sich für
